Michelle Hughes1, Taha Qazi, Adam Berg, Janice Weinberg, Xinhua Chen, Ciaran P Kelly, Francis A Farraye. 1. *Department of Internal Medicine, Boston University School of Medicine, Boston, Massachusetts; †Department of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts; ‡Harvard Medical School, Boston, Massachusetts; §Section of Gastroenterology, Boston Medical Center, Boston, Massachusetts; ‖Syracuse Gastroenterological Associates, Syracuse, New York; ¶Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts; **Boston University School of Medicine, Boston, Massachusetts; and ††Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) affects patients with inflammatory bowel disease (IBD). The aim of this study was to compare humoral response to C. difficile toxins in IBD patients and control outpatients. METHODS: We prospectively followed adult IBD patients and control subjects with serum and stool samples obtained at enrollment and during periods of CDI and tested by PCR. Semiquantitative serum levels of IgM, IgG, and IgA to C. difficile toxins A and B were measured. RESULTS: Overall, 119 stool and 117 serum samples were obtained from 150 subjects. Different levels of IgA to toxin A (P = 0.0016) and toxin B (P = 0.0468) were noted between different IBD groups. Toxin A IgA levels were higher in the Crohn's disease group (P = 0.0321) and ileal pouch anal anastomosis (IPAA) group (P = 0.001) compared with the ulcerative colitis (UC) group, and toxin B IgA levels were higher in the IPAA group compared with the UC group (P = 0.0309). There were lower levels of toxin A IgA in IBD patients compared with those in subjects without new CDI (P = 0.0488) and higher levels in IBD patients with compared with those in subjects without CDI history before enrollment (P = 0.016). There were nonsignificant lower toxin A IgG levels in IBD patients compared with those in subjects without prior CDI (P = 0.095) and higher levels in control subjects with a history of CDI compared with IBD patients with prior CDI (P = 0.049). CONCLUSIONS: Patients with UC have lower IgA levels to C. difficile toxins compared with those with Crohn's disease and those after IPAA. Patients with IBD with prior CDI failed to demonstrate any increase in antitoxin IgG. Our findings suggest that IBD patients may benefit from immunization strategies targeting C. difficile toxins.
BACKGROUND:Clostridium difficileinfection (CDI) affects patients with inflammatory bowel disease (IBD). The aim of this study was to compare humoral response to C. difficile toxins in IBDpatients and control outpatients. METHODS: We prospectively followed adult IBDpatients and control subjects with serum and stool samples obtained at enrollment and during periods of CDI and tested by PCR. Semiquantitative serum levels of IgM, IgG, and IgA to C. difficile toxins A and B were measured. RESULTS: Overall, 119 stool and 117 serum samples were obtained from 150 subjects. Different levels of IgA to toxin A (P = 0.0016) and toxin B (P = 0.0468) were noted between different IBD groups. Toxin A IgA levels were higher in the Crohn's disease group (P = 0.0321) and ileal pouch anal anastomosis (IPAA) group (P = 0.001) compared with the ulcerative colitis (UC) group, and toxin B IgA levels were higher in the IPAA group compared with the UC group (P = 0.0309). There were lower levels of toxin A IgA in IBDpatients compared with those in subjects without new CDI (P = 0.0488) and higher levels in IBDpatients with compared with those in subjects without CDI history before enrollment (P = 0.016). There were nonsignificant lower toxin A IgG levels in IBDpatients compared with those in subjects without prior CDI (P = 0.095) and higher levels in control subjects with a history of CDI compared with IBDpatients with prior CDI (P = 0.049). CONCLUSIONS:Patients with UC have lower IgA levels to C. difficile toxins compared with those with Crohn's disease and those after IPAA. Patients with IBD with prior CDI failed to demonstrate any increase in antitoxin IgG. Our findings suggest that IBDpatients may benefit from immunization strategies targeting C. difficile toxins.
Authors: Joseph F Rodemann; Erik R Dubberke; Kimberly A Reske; Da Hea Seo; Christian D Stone Journal: Clin Gastroenterol Hepatol Date: 2007-03 Impact factor: 11.382
Authors: Vivian G Loo; Anne-Marie Bourgault; Louise Poirier; François Lamothe; Sophie Michaud; Nathalie Turgeon; Baldwin Toye; Axelle Beaudoin; Eric H Frost; Rodica Gilca; Paul Brassard; Nandini Dendukuri; Claire Béliveau; Matthew Oughton; Ivan Brukner; Andre Dascal Journal: N Engl J Med Date: 2011-11-03 Impact factor: 91.245
Authors: Evelyn M Clayton; Mary C Rea; Fergus Shanahan; Eamonn M M Quigley; Barry Kiely; Colin Hill; R Paul Ross Journal: Am J Gastroenterol Date: 2009-03-24 Impact factor: 10.864
Authors: Suchitra K Hourigan; Sankar R Chirumamilla; Tracy Ross; Jonathan E Golub; Shervin Rabizadeh; Shehzad A Saeed; Charles O Elson; Ciaran P Kelly; Karen C Carroll; Maria Oliva-Hemker; Cynthia Sears Journal: Inflamm Bowel Dis Date: 2013-12 Impact factor: 5.325
Authors: Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: Larry K Kociolek; Robyn O Espinosa; Dale N Gerding; Alan R Hauser; Egon A Ozer; Maria Budz; Aakash Balaji; Xinhua Chen; Robert R Tanz; Nazli Yalcinkaya; Margaret E Conner; Tor Savidge; Ciaran P Kelly Journal: Clin Infect Dis Date: 2020-05-06 Impact factor: 9.079
Authors: Masoumeh Azimirad; Sara Mohammad Ali Gol; Ehsan Javanmard; Hamed Mirjalali; Abbas Yadegar; Hamid Asadzadeh Aghdaei; Shabnam Shahrokh; Hedieh Balaii; Amir Sadeghi; Mohammad Reza Zali Journal: Turk J Gastroenterol Date: 2021-06 Impact factor: 1.852
Authors: Dejan Micic; Andres Yarur; Alex Gonsalves; Vijaya L Rao; Susan Broadaway; Russell Cohen; Sushila Dalal; John N Gaetano; Laura R Glick; Ayal Hirsch; Joel Pekow; Atsushi Sakuraba; Seth T Walk; David T Rubin Journal: Dig Dis Sci Date: 2018-02-08 Impact factor: 3.199
Authors: Carolyn D Alonso; Konstantinos Papamichael; Rebecca Sprague; Caitlin Barrett; Anne J Gonzales-Luna; Kaitlyn Daugherty; Kevin W Garey; Javier Villafuerte-Gálvez; Hua Xu; Qianyun Lin; Lamei Wang; Xinhua Chen; Nira R Pollock; Ciarán P Kelly Journal: Open Forum Infect Dis Date: 2021-06-01 Impact factor: 3.835